NasdaqGS:INSMBiotechs
Can Insmed (INSM) Stay Reasonable After Its Japan Approval?
Insmed stock has delivered a very large gain over the past three years, yet current valuation checks lean toward the shares being priced on the expensive side rather than as a clear bargain. After that run, investors are weighing the recent pullback and mixed valuation signals against fresh product news from the company.
Insmed has returned roughly 4.5 times over three years, which puts recent short term weakness into the context of a much longer stretch of strong share performance.
Approval...